A Single Centre Two Part Randomized Phase I Study to Assess the Pharmacokinetics of an ER Formulation of AZD2516 and to Assess the Safety, Tolerability and Pharmacokinetics of AZD2516 After Multiple Ascending Doses in Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2016
At a glance
- Drugs AZD 2516 (Primary)
- Indications Gastro-oesophageal reflux; Neuropathic pain
- Focus Adverse reactions
- Sponsors AstraZeneca
- 07 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Feb 2011 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
- 13 Aug 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.